Arkolith/Funds/Checkpoint Capital L.P.

Checkpoint Capital L.P.

CIK 1977548
Holdings as of Jun 30, 2026·disclosed Aug 14, 2026·~45-day 13F lag·13F-HR
Active Filer

Checkpoint Capital L.P. holds a concentrated book of 6 stocks worth $389.8M as of Q2 2026 (disclosed Aug 14, 2026, a ~45-day 13F lag). This quarter they opened Corcept Therapeutics Inc and trimmed Rhythm Pharmaceuticals Inc. Their largest long position is Rhythm Pharmaceuticals Inc at 34% of the equity book.

Opened
1
bought for the first time
Sold out
2
exited the position entirely

Concentration

Top-heavy: concentrated book

Top 5 holdings
100%
Top 10 holdings
100%
Top 20 holdings
100%

Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.

Direct sector allocation

100% mapped to company sectors

Health Care
100%

Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.

Biggest moves: latest quarter

Estimated $ traded · quarter-end prices, no cost basis

Bought
Trimmed / exited

Funds with the most overlap

Other tracked managers holding the same core names as Checkpoint Capital L.P.

Manager / fundShared namesTheir $ in those
FMR LLC9 / 6$6.5B
BlackRock, Inc.9 / 6$4.4B
PRICE T ROWE ASSOCIATES INC /MD/9 / 6$3.3B
JANUS HENDERSON GROUP PLC9 / 6$3.1B
STATE STREET CORP9 / 6$2.3B
GEODE CAPITAL MANAGEMENT, LLC9 / 6$1.7B
GOLDMAN SACHS GROUP INC9 / 6$875.7M
MORGAN STANLEY9 / 6$730.4M

Ranked by the share of each fund's own book sitting in the names it shares with Checkpoint Capital L.P.: only funds sharing at least a tenth of the book qualify. Index giants, bank custody books and market makers are excluded. They hold everything, so their overlap says nothing.

Holdings: largest first

Bars show each stock's share of the portfolio. Click a row for its position history.

6 positions
#SecurityValueShares% PortLast moveHistory
1Rhythm Pharmaceuticals Inc
COM
$131.7M1.19M
33.8%
−3.4%
Reduced · −41K sh
2Argenx SE
SPONSORED ADR
$121.8M131.3K
31.3%
−14%
Reduced · −22K sh
3Revolution Medicines Inc
COM
$76.9M410.4K
19.7%
+56%
Added · +148K sh
4Cytokinetics Inc
COM NEW
$40.5M475.0K
10.4%
+164%
Added · +295K sh
5Disc Medicine Inc
COM
$17.6M240.1K
4.5%
−16%
Reduced · −47K sh
6Trevi Therapeutics Inc
COM
$1.4M75.0K
0.4%
+50%
Added · +25K sh
Showing all 6 positions
Build

Build on this 13F portfolio

The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.

Build

Ask your agent what Checkpoint Capital L.P. owns

This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.

Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/funds/1977548/holdings"
Ask your agent
Use Arkolith to show Checkpoint Capital L.P.'s latest
holdings, largest changes, and filing provenance.

Filing history

As-of date vs the date the SEC received each filing

QuarterAs ofFiledPositionsValueForm
Q2 2026Jun 30, 2026Aug 14, 20266$389.8M13F-HR
Q1 2026Mar 31, 2026May 15, 20268$278.7M13F-HR
Q4 2025Dec 31, 2025Feb 17, 20267$320.1M13F-HR
Q3 2025Sep 30, 2025Nov 14, 202510$298.5M13F-HR
Q2 2025Jun 30, 2025Aug 14, 20258$214.6M13F-HR

Data source

Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.